Figure 7. Immunisation with Polypeptides generates protective immunity against lethal challenge with six different clinical MRSA isolates.
Survival of Polypeptides-immunised mice following challenge with clinical MRSA isolates (n = 20 for every isolate, of which n = 10 for Polypeptides-immunised mice and n = 10 for PBS-immunised mice). Compared with animals receiving mock-immunization (PBS), the significance of protective immunity generated by the combined vaccine was measured with Fisher’s exact test: (A) CQ19: P < 0.001; (B) SJZ30: P < 0.001; (C) BJ2: P = 0.005; (D) SJZ18: P = 0.003; (E) GZ9: P = 0.001; (F) MRSA252: P < 0.001.